Alexander Drilon, MD
Larotrectinib (Vitrakvi) has shown promising activity in patients with TRK
fusion–positive cancers who also have brain metastases or primary central nervous system (CNS) tumors, said Alexander Drilon, MD. Results from 2 clinical trials further underscore the need for expanded testing for these fusions across all tumor types.
... to read the full story